Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 4/2016

01-08-2016 | SHORT REPORT

Why balls are not put inside the basket? A reflection on testicular cancer clinical trial design

Authors: Hampig Raphael Kourie, Fouad Aoun

Published in: Investigational New Drugs | Issue 4/2016

Login to get access

Summary

New concepts of trial design are being developed based on biomarkers, namely basket and umbrella trials. Basket trials appear optimally positioned to evaluate new molecular markers for testicular germ cell tumors, a rare heterogeneous disease with relatively few molecular alterations. However, not uncommonly, the “balls” fall outside the “basket”. In this short communication, we discussed the different causes limiting the inclusion of TGCT in basket trials and we proposed a new design for trials suitable for this malignancy.
Literature
1.
Catenacci DV (2015) Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol 9:967–996CrossRefPubMed
2.
3.
Jacobsen C, Honecker F (2015) Cisplatin resistance in germ cell tumours: models and mechanisms. Andrology 3:111–121CrossRefPubMed
4.
Cavallo F, Feldman DR, Barchi M (2013) Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors. Int J Dev Biol 57:273–280CrossRefPubMed
5.
Gillis AJ, Rijlaarsdam MA, Eini R, et al. (2013) Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of(testicular) germ cell cancer patients: a proof of principle. Mol Oncol 7:1083–1092CrossRefPubMed
6.
Dieckmann KP, Spiekermann M, Balks T, et al. (2012) MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours. Br J Cancer 107:1754–1760CrossRefPubMedPubMedCentral
7.
Liu L, Lian J, Zhang H, et al. (2013) MicroRNA-302a sensitizes testicular embryonal carcinoma cells to cisplatin-induced cell death. J Cell Physiol 228:2294–2304CrossRefPubMed
8.
Huang H, Tian H, Duan Z, et al. (2014) microRNA-383 impairs phosphorylation of H2AX by targeting PNUTS and inducing cell cycle arrest in testicular embryonal carcinoma cells. Cell Signal 26:903–911CrossRefPubMed
9.
Koster R, di Pietro A, Timmer-Bosscha H, et al. (2010) Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest 120:3594–3605CrossRefPubMedPubMedCentral
10.
Koster R, Timmer-Bosscha H, Bischoff R, et al. (2011) Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells viathe Fas/FasL pathway. Cell Death Dis 21:148CrossRef
Metadata
Title
Why balls are not put inside the basket? A reflection on testicular cancer clinical trial design
Authors
Hampig Raphael Kourie
Fouad Aoun
Publication date
01-08-2016
Publisher
Springer US
Published in
Investigational New Drugs / Issue 4/2016
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-016-0338-7

Other articles of this Issue 4/2016

Investigational New Drugs 4/2016 Go to the issue

PHASE I STUDIES

Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin

PRECLINICAL STUDIES

Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice

PRECLINICAL STUDIES

AZD9291 overcomes T790 M-mediated resistance through degradation of EGFRL858R/T790M in non-small cell lung cancer cells

REVIEW

CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies

PHASE II STUDIES

Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer

PRECLINICAL STUDIES

Peloruside A, a microtubule-stabilizing agent, induces aneuploidy in ovarian cancer cells

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

Perioperative chemo outplays neoadjuvant CRT in esophageal cancer

05-06-2024 Esophageal Cancer News

LAURA heralds practice change for locally advanced NSCLC

03-06-2024 NSCLC News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits